L-ornithine L-aspartate

ApprovedSmall molecule

IInstitute of Liver and Biliary Sciences, India

L-ornithine L-aspartate is one of 113 small molecule programs targeting Acute Liver Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Liver FailureActive, not recruiting

EncephalopathyActive, not recruiting

Liver DiseaseActive, not recruiting

Breast CancerActive, not recruiting

Acute Liver FailurePhase 2

Active, not recruiting

EncephalopathyApproved

Active, not recruiting

Liver DiseasePreclinical

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

L-ornithine L-aspartate

IInstitute of Liver and Biliary Sciences, India

Approved

1 2

MS Contin

Merck & Co.

Preclinical

2 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 5

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 6

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 7

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Breast Cancer

NCT07117630

Clinical

Trials by Indication[1]

Encephalopathy6 trials

Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy

Unknown status·JJinnah Postgraduate Medical Centre·Phase 4·NCT05920213·360 enrolled

L-ornithine L-aspartate in Overt Hepatic Encephalopathy

Completed·—·Phase 4·NCT01722578·200 enrolled

Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy

Completed·—·Phase 3·NCT00433368·108 enrolled

Show 3 more trials

Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding

Completed·HHospital General de Mexico·Phase 4·NCT02158182·88 enrolled

Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 4·NCT00896831·96 enrolled

Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.

Completed·CCentro Regional para el Estudio de las Enfermedades Digestivas·Phase 4·NCT01041755·30 enrolled

Acute Liver Failure2 trials

Efficacy of L-ornithine L-aspartate and Therapeutic Plasma Exchange Versus Plasma Exchange Alone in Lowering Ammonia and Improving Outcomes in Pediatric Acute Liver Failure.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05778461·32 enrolled

Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure

Unknown status·—·Phase 2·NCT00470314·150 enrolled

Effectiveness1 trial

The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS

Completed·—·Phase 2/3·NCT01440829·40 enrolled

Gut Microbiome1 trial

Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

Active, not recruiting·MMedical University of Graz·Phase 4·NCT05737030·55 enrolled

Liver Disease1 trial

Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.

Completed·IImperial College London·N/A·NCT00305591·50 enrolled

1 more indication

Breast Cancer1 trial

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Recruiting·FFudan University·Phase 2·NCT07117630·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for L-ornithine L-aspartate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-ornithine L-aspartate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-ornithine L-aspartate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IInstitute of Liver and Biliary Sciences, India

L-ornithine L-aspartate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Encephalopathy6 trials

Acute Liver Failure2 trials

Effectiveness1 trial

Gut Microbiome1 trial

Liver Disease1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News